175 related articles for article (PubMed ID: 37729198)
1. An antioxidant feedforward cycle coordinated by linker histone variant H1.2 and NRF2 that drives nonsmall cell lung cancer progression.
Chen Y; Shi J; Wang X; Zhou L; Wang Q; Xie Y; Peng C; Kuang L; Yang D; Yang J; Yang C; Li X; Yuan Y; Zhou Y; Peng A; Zhang Y; Chen H; Liu X; Zheng L; Huang K; Li Y
Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2306288120. PubMed ID: 37729198
[TBL] [Abstract][Full Text] [Related]
2. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
6. PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress.
Chen X; Cao X; Xiao W; Li B; Xue Q
Aging (Albany NY); 2020 Jan; 12(1):122-137. PubMed ID: 31899687
[TBL] [Abstract][Full Text] [Related]
7. IL-36γ and IL-36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress-Induced Cell Death.
Wang P; Yang W; Guo H; Dong HP; Guo YY; Gan H; Wang Z; Cheng Y; Deng Y; Xie S; Yang X; Lin D; Zhong B
Adv Sci (Weinh); 2021 Oct; 8(19):e2101501. PubMed ID: 34369094
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells.
Zhao Q; Mao A; Yan J; Sun C; Di C; Zhou X; Li H; Guo R; Zhang H
Int J Oncol; 2016 Feb; 48(2):765-73. PubMed ID: 26691854
[TBL] [Abstract][Full Text] [Related]
9. The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours.
Hannon Barroeta P; O'Sullivan MJ; Zisterer DM
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8379-8391. PubMed ID: 37079050
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
11. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance.
Singh A; Bodas M; Wakabayashi N; Bunz F; Biswal S
Antioxid Redox Signal; 2010 Dec; 13(11):1627-37. PubMed ID: 20446773
[TBL] [Abstract][Full Text] [Related]
12. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein 1 mediates 15-deoxy-Δ(12,14)-prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells.
Song NY; Kim DH; Kim EH; Na HK; Kim NJ; Suh YG; Surh YJ
Chem Res Toxicol; 2011 Aug; 24(8):1231-41. PubMed ID: 21728338
[TBL] [Abstract][Full Text] [Related]
14. Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS‑mutated lung cancer cells.
Wang M; Chen X; Fu G; Ge M
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36222298
[TBL] [Abstract][Full Text] [Related]
15. The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer.
Chen Z; Ye X; Tang N; Shen S; Li Z; Niu X; Lu S; Xu L
Br J Pharmacol; 2014 Jul; 171(13):3196-211. PubMed ID: 24571482
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
17. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.
Zhang C; Yang Y; Liang W; Wang T; Wang S; Wang X; Wang Y; Jiang H; Feng H
Brain Res Bull; 2019 Mar; 146():287-301. PubMed ID: 30690059
[TBL] [Abstract][Full Text] [Related]
19. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
20. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
